, The International Society for the Study of Vascular Anomalies, 2015.

M. Wassef and O. Enjolras, Les malformations vasculaires superficielles: classification et histopathologie, Ann Pathol, vol.19, pp.253-264, 1999.

M. Wassef, F. Blei, D. Adams, A. Alomari, E. Baselga et al., Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies, Pediatrics, vol.136, pp.203-214, 2015.

O. Enjolras and J. B. Mulliken, Vascular tumors and vascular malformations (new issues), Adv Dermatol, vol.13, pp.375-423, 1997.

R. Sidbury, Update on vascular tumors of infancy, Curr Opin Pediatr, vol.22, pp.432-437, 2010.

D. M. Adams and A. Hammill, Other vascular tumors, Semin Pediatr Surg, vol.23, pp.173-177, 2014.

S. Sommer, D. C. Seukeran, and R. A. Sheehan-dare, Efficacy of pulsed dye laser treatment of port wine stain malformations of the lower limb, Br J Dermatol, vol.149, pp.770-775, 2003.

M. A. Reinhardt, S. C. Nelson, S. F. Sencer, B. C. Bostrom, S. C. Kurachek et al., Treatment of childhood lymphangiomas with interferon-alpha, J Pediatr Hematol Oncol, vol.19, pp.232-236, 1997.

R. Dickerhoff and V. U. Bode, Cyclophosphamide in nonresectable cystic hygroma, Lancet, vol.335, pp.1474-1475, 1990.

M. Ozeki, K. Kanda, N. Kawamoto, H. Ohnishi, A. Fujino et al., Propranolol as an alternative treatment option for pediatric lymphatic malformation, Tohoku J Exp Med, vol.229, pp.61-66, 2013.

S. J. Boardman, L. A. Cochrane, D. Roebuck, M. J. Elliott, and B. E. Hartley, Multimodality treatment of pediatric lymphatic malformations of the head and neck using surgery and sclerotherapy, Arch Otolaryngol Head Neck Surg, vol.136, pp.270-276, 2010.

E. Le-fourn, D. Herbreteau, C. Papagiannaki, L. G. Sirinelli, D. Goga et al., Efficacy and safety of embolization in arteriovenous malformations of the extremities and head and neck: a retrospective study of 32 cases, Eur J Dermatol, vol.25, pp.52-56, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02630885

C. Léauté-labrèze, D. De-la-roque, E. Hubiche, T. Boralevi, F. Thambo et al., Propranolol for severe hemangiomas of infancy, N Engl J Med, vol.358, pp.2649-2651, 2008.

L. E. Bartoshesky, M. Bull, and M. Feingold, Corticosteroid treatment of cutaneous hemangiomas: how effective? A report on 24 children, Clin Pediatr (Phila), vol.17, pp.629-638, 1978.

C. Haisley-royster, O. Enjolras, I. J. Frieden, M. Garzon, M. Lee et al., Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine, J Pediatr Hematol Oncol, vol.24, pp.459-462, 2002.

N. M. Bauman, D. K. Burke, and R. J. Smith, Treatment of massive or life-threatening hemangiomas with recombinant alpha(2a)-interferon, Otolaryngol Head Neck Surg, vol.17, pp.99-110, 1997.

B. Hu, R. Lachman, J. Phillips, S. K. Peng, and L. Sieger, Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D, J Pediatr Hematol Oncol, vol.20, pp.567-569, 1998.

M. Hochman, D. M. Adams, and T. D. Reeves, Current knowledge and management of vascular anomalies: I. Hemangiomas, Arch Facial Plast Surg, vol.13, pp.145-151, 2011.

R. G. Azizkhan, Complex vascular anomalies, Pediatr Surg Int, vol.29, pp.1023-1038, 2013.

J. Blatt, J. Stavas, B. Moats-staats, J. Woosley, and D. S. Morrell, Treatment of childhood kaposiform hemangioendothelioma with sirolimus, Pediatr Blood Cancer, vol.55, pp.1396-1398, 2010.

A. M. Hammill, M. S. Wentzel, A. Gupta, S. Nelson, A. Lucky et al., Sirolimus for the treatment of complicated vascular anomalies in children, Pediatr Blood Cancer, vol.57, pp.1018-1024, 2011.

D. J. Marsh, T. N. Trahair, J. L. Martin, W. Y. Chee, J. Walker et al., Rapamycin treatment for a child with germline PTEN mutation, Nat Clin Pract Oncol, vol.5, pp.357-361, 2008.

C. M. Hartford and M. J. Ratain, Rapamycin: something old, something new, sometimes borrowed and now renewed, Clin Pharmacol Ther, vol.82, pp.381-388, 2007.

B. Perry, J. Banyard, E. R. Mclaughlin, R. Watnick, A. Sohn et al., AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo, Arch Dermatol, vol.143, pp.504-506, 2007.

S. N. Sehgal, H. Baker, and C. Vézina, Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization, J Antibiot (Tokyo), vol.28, pp.727-732, 1975.

B. D. Kahan, J. Y. Chang, and S. N. Sehgal, Preclinical evaluation of a new potent immunosuppressive agent, rapamycin, Transplantation, vol.52, pp.185-191, 1991.

B. Venugopal, J. Ansari, M. Aitchison, L. M. Tho, R. Campbell et al., Efficacy of temsirolimus in metastatic chro-mTOR inhibitors and vascular anomalies mophobe renal cell carcinoma, BMC Urol, vol.13, p.26, 2013.

B. D. Kahan, Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group, Lancet, vol.356, pp.194-202, 2000.

K. Budde, F. Lehner, C. Sommerer, P. Reinke, W. Arns et al., Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study, Am J Transplant, vol.15, pp.119-128, 2015.

T. Dumortier, M. Looby, O. Luttringer, G. Heimann, J. Klupp et al., Estimating the contribution of everolimus to immunosuppressive efficacy when combined with tacrolimus in liver transplantation: a model-based approach, Clin Pharmacol Ther, vol.97, pp.411-418, 2015.

G. Brandhorst, G. Tenderich, A. Zittermann, C. Oezpeker, R. Koerfer et al., Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor, Ther Drug Monit, vol.30, pp.113-116, 2008.

B. Coiffier, Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma, Clin Lymphoma Myeloma Leuk, vol.13, pp.351-359, 2013.

X. Tan, Y. Liu, J. Hou, and G. Cao, Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus, Onco Targets Ther, vol.8, pp.313-321, 2015.

D. A. Yardley, S. Noguchi, K. I. Pritchard, H. A. Burris, J. Baselga et al., Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer: BOLERO-2 final progression-free survival analysis, Adv Ther, vol.30, pp.870-884, 2013.

C. Lombard-bohas, J. C. Yao, T. Hobday, E. Van-cutsem, E. M. Wolin et al., Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors. A subgroup analysis of the phase III RADIANT-3 trial, Pancreas, vol.44, pp.181-189, 2015.

D. N. Franz, Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex, Biologics, vol.7, pp.211-221, 2013.

M. Mita, K. Sankhala, A. Mita, A. Giles, and F. , Deforolimus (AP23573) a novel mTOR inhibitor in clinical development, Expert Opin Investig Drugs, vol.17, pp.1947-1954, 2008.

D. Mahalingam, K. Sankhala, A. Mita, F. J. Giles, and M. M. Mita, Targeting the mTOR pathway using deforolimus in cancer therapy, Future Oncol, vol.5, pp.291-303, 2009.

D. Tsoref, S. Welch, S. Lau, J. Biagi, K. Tonkin et al., Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer, Gynecol Oncol, vol.135, pp.184-189, 2014.

W. H. Tan, H. N. Baris, P. E. Burrows, C. D. Robson, A. I. Alomari et al., The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management, J Med Genet, vol.44, pp.594-602, 2007.

M. Guba, P. Von-breitenbuch, M. Steinbauer, G. Koehl, S. Flegel et al., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat Med, vol.8, pp.128-135, 2002.

P. Baldo, S. Cecco, E. Giacomin, R. Lazzarini, and R. B. , Marastoni S. MTOR pathway and mTOR inhibitors as agents for cancer therapy, Curr Cancer Drug Targets, vol.8, pp.647-665, 2008.

L. Huu, A. R. Jokinen, C. H. Rubin, B. P. Mihm, M. C. Weiss et al., Expression of prox1, lymphatic endothelial nuclear transcription factor, in Kaposiform hemangioendothelioma and tufted angioma, Am J Surg Pathol, vol.34, pp.1563-1573, 2010.

M. V. Flores, C. J. Hall, K. E. Crosier, and P. S. Crosier, Visualization of embryonic lymphangiogenesis advances the use of the zebrafish model for research in cancer and lymphatic pathologies, Dev Dyn, vol.239, pp.2128-2135, 2010.

S. Kobayashi, T. Kishimoto, S. Kamata, M. Otsuka, M. Miyazaki et al., Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis, Cancer Sci, vol.98, pp.726-733, 2007.

K. Matthews, J. Gossett, P. V. Kappelle, G. Jellen, and E. Pahl, Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: intermediate experience in pediatric heart transplantation recipients, Pediatr Transplant, vol.14, pp.402-408, 2010.

G. Yang, L. Yang, X. Yang, X. Shi, J. Wang et al., Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: a systematic review and meta-analysis, Exp Ther Med, vol.9, pp.626-630, 2015.

E. Raymond, J. Alexandre, S. Faivre, K. Vera, E. Materman et al., Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer, J Clin Oncol, vol.22, pp.2336-2347, 2004.

K. W. Yee, Z. Zeng, M. Konopleva, S. Verstovsek, F. Ravandi et al., Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies, Clin Cancer Res, vol.12, pp.5165-5173, 2006.

S. P. Chawla, A. W. Tochler, A. P. Staddon, S. M. Schetze, D. 'amato et al., Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas, J Clin Oncol (Meeting Abstracts), vol.24, p.9505, 2006.

L. Champion, M. Stern, D. Israël-biet, M. F. Mamzer-bruneel, M. N. Peraldi et al., Brief communication: sirolimusassociated pneumonitis: 24 cases in renal transplant recipients, Ann Intern Med, vol.144, pp.505-509, 2006.